Sensitivity and specificity of screening instruments. Data are percentage (95% CI).
| All Participants, n = 170–185 | Participants Without Previous PsA Diagnosis, n = 88–95 | Participants Without Previous PsA Diagnosis and Without Current Immunomodulators, n = 54–58 | ||||
|---|---|---|---|---|---|---|
| Sensitivity | Specificity | Sensitivity | Specificity | Sensitivity | Specificity | |
| PEST | 85 (79–91) | 45 (31–59) | 69 (56–82) | 47 (33–61) | 70 (53–88) | 55 (37–72) |
| ToPAS | 75 (67–82) | 55 (41–70) | 60 (53–81) | 55 (35–65) | 60 (41–79) | 52 (34–70) |
| PASE47 | 68 (61–76) | 50 (36–64) | 63 (47–75) | 52 (44–72) | 62 (39–75) | 60 (42–78) |
| PASE44 | 78 (73–86) | 40 (26–53) | 76 (57–83) | 41 (32–61) | 73 (51–85) | 47 (29–65) |
PsA: psoriatic arthritis; PEST: Psoriasis Epidemiology Screening project; ToPAS: the Toronto Psoriatic Arthritis Screen; PASE: Psoriatic Arthritis Screening and Evaluation.